arrow
返回
T

Thomas Bachelot

centre leon berard

65H指数
553论文数
2.4W被引数
收录论文 198
发表时间
Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局:来自法国多中心ESME数据库的见解
errBreast
IF7.9
err2026-09-27
err0
errOAAI
errWilliam Jacot; Pauline Macouillard; Suyuan Zhang; Danalyn Byng; Shannon Hunter; Vincent Massard; Jean-Sébastien Frenel; David Pérol; Etienne Brain; Audrey Mailliez; Thomas Bachelot; Monica Arnedos; Lise Bosquet; Véronique Diéras
err分享
err收藏
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trialPACS-01试验中预测HR阳性乳腺癌患者从多西他赛化疗中获益
errBreast
IF7.9
err2026-08-07
err0
errOAAI
errFrédérique Penault-Llorca; Amelie Lusque; Thomas Filleron; Kevin Tran; Lili Du; Rick Baehner; Florence Dalenc; Magali Lacroix-Triki; Thomas Bachelot; Fabrice Andre; Pascal Boucher; Jérôme Lemonnier; W. Fraser Symmans
err分享
err收藏
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.HER2阴性低表达雌激素和孕激素受体转移性乳腺癌患者的特征和结局:多中心ESME队列研究
err2026-05-18
err0
errOAAI
errMarie Alexandre; Eva Teruel; Florence Dalenc; Thibaut de la Motte Rouge; Etienne Brain; Vincent Massard; Monica Arnedos; Audrey Mailliez; Jean-Marc Ferrero; Thomas Bachelot; Isabelle Desmoulins; Marie-Ange Mouret-Reynier; Christelle Levy; Antony Gonçalves; Anca Berghian; Thierry Petit; Jean-Sébastien Frenel; Anne-Laure Martin; Thomas Grinda; William Jacot
err分享
err收藏
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trialDatopotamab deruxtecan在未经治疗的晚期三阴性乳腺癌患者中的TROPION-Breast02: 一项随机,开放标签,国际,III期试验
err2026-04-03
err0
PREAI
errR. Dent; Z. Shao; P. Schmid; J. Cortes; D.W. Cescon; S. Saji; K.H. Jung; T. Bachelot; S. Wang; E.M. Ramírez; G. Basaran; A. Stradella; R. Mathiba; S.-C. Chen; K. Shen; Á. Wéber; N. Battelli; N. Niikura; T. Luo; Y.S. Chae
err分享
err收藏
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势
err2025-12-05
err0
PREAI
errFanny Bouteiller; Sophie Gourgou; Michaël Bringuier; Angéline Galvin; Audrey Mailliez; Nicolas Bertrand; Mony Hung; Jean-Sébastien Frenel; Vincent Massard; Thomas Bachelot; Carole Plumio; Anthony Gonçalves; Christelle Levy; Lise Bosquet; William Jacot; Suzette Delaloge; Thomas Grinda; Carine Bellera
err分享
err收藏
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerESR1突变检测在转移性乳腺癌中的动力学及决定因素
err2025-11-17
err0
PREAI
errL. Cabel; F. Berger; T. Bachelot; B. Pistilli; F. Dalenc; T.de la Motte Rouge; R. Sabatier; A. Lortholary; S. Marques; J. Vibert; S. Renault; A.C. Hardy-Bessard; S. Delaloge; A. Pradines; C. Callens; F.C. Bidard
err分享
err收藏
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortCDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究
err2025-09-17
err0
PREAI
errR. Varnier; D. Pérol; W. Jacot; A. Mailliez; V. Diéras; F. Dalenc; A. Gonçalves; C. Levy; M. Arnedos; J.-S. Frenel; C. Bailleux; V. Massard; E. Brain; B. Sauterey; A.-M. Savoye; L. Bosquet; J.-C. Thery; T. Petit; T. Bachelot; T. Grinda; I. Ray-Coquard
err分享
err收藏
Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach通过计算方法发现侵袭性乳腺癌中表观遗传沉默的肿瘤抑制基因
err2025-06-01
err0
errOAAI
errVitte, Anne-Laure; Chuffart, Florent; Jacquet, Emmanuelle; Nika, Eleni; Mousseau, Mireille; Jung, Ina; Tabone-Eglinger, Severine; Bachelot, Thomas; Rousseaux, Sophie; Khochbin, Saadi; Bourova-Flin, Ekaterina
err分享
err收藏
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2-early breast cancer
err2025-02-27
err0
errOAAI
errHamilton, Erika P.; Loibl, Sibylle; Bachelot, Thomas; Gnant, Michael; Niikura, Naoki; Park, Yeon Hee; Tolaney, Sara M.; Pistilli, Barbara; Rastogi, Priya; Saini, Kamal S.; Gioni, Ioanna; Johnston, Simon; Nunes, Raquel; Quintana, Angela; Stuart, Mary; Syta, Emilia; Walding, Andrew; Klinowska, Teresa; Mayer, Ingrid A.
err分享
err收藏
Expert HER2-positive Volkmar Julia Emilie a The University b Centre c Department
err2025-01-01
err0
errOAAI
errMueller, Volkmar; Bachelot, Thomas; Curigliano, Giuseppe; de Azambuja, Evandro; Furtner, Julia; Gempt, Jens; Jereczek-Fossa, Barbara Alicja; Jerzak, Katarzyna J.; Le Rhun, Emilie; Palmieri, Carlo; Pravettoni, Gabriella; Saura, Cristina; Bartsch, Rupert
err分享
err收藏
Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation☆
err2024-12-01
err0
errOAAI
errAntoine, Alison; Perol, David; Robain, Mathieu; Bachelot, Thomas; Choquet, Remy; Jacot, William; Yahia, Bechir Ben Hadj; Grinda, Thomas; Delaloge, Suzette; Lasset, Christine; Drouet, Youenn
err分享
err收藏
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors
err2024-08-02
err0
errOAAI
errSablin, Marie-Paule; Gestraud, Pierre; Jonas, Sarah Flora; Lamy, Constance; Lacroix-Triki, Magali; Bachelot, Thomas; Filleron, Thomas; Lacroix, Ludovic; Tran-Dien, Alicia; Jezequel, Pascal; Mauduit, Marjorie; Barros Monteiro, Janice; Jimenez, Marta; Michiels, Stefan; Attignon, Valery; Soubeyran, Isabelle; Driouch, Keltouma; Servant, Nicolas; Le Tourneau, Christophe; Kamal, Maud; Andre, Fabrice; Bieche, Ivan
err分享
err收藏
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial曲妥珠单抗deruxtecan与曲妥珠单抗emtansine治疗HER2-positive转移性乳腺癌: DESTINY-Breast03试验的长期生存分析
err2024-06-02
err6
errOAAI
errCortes, Javier; Hurvitz, Sara A.; Im, Seock-Ah; Iwata, Hiroji; Curigliano, Giuseppe; Kim, Sung-Bae; Chiu, Joanne W. Y.; Pedrini, Jose L.; Li, Wei; Yonemori, Kan; Bianchini, Giampaolo; Loi, Sherene; Borges, Giuliano S.; Wang, Xian; Bachelot, Thomas; Nakatani, Shunsuke; Ashfaque, Shahid; Liang, Zhengkang; Egorov, Anton; Hamilton, Erika
err分享
err收藏
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
err2024-05-02
err0
PREAI
errLynce, Filipa; Niman, Samuel; Goncalves, Anthony; Kai, Megumi; Ryan, Sean; Troll, Elizabeth; Layman, Rachel; Giordano, Antonio; Nasrazadani, Azadeh; Nakhlis, Faina; Bellon, Jennifer; Warren, Laura; Block, Caroline; Schumer, Susan; Lucci, Anthony; Krishnamurthy, Savitri; Lerebours, Florence; Dalenc, Florence; Levy, Christelle; Petit, Thierry; Leheurteur, Marianne; Bachelot, Thomas; Tredan, Olivier; Ladoire, Sylvain; Almeida, Leonor Lopez; Zemmour, Christophe; Tolaney, Sara; Valero, Vicente; Bertucci, Francois; Regan, Meredith; Woodward, Wendy
err分享
err收藏
Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation
err2024-05-02
err0
PREAI
errGoetz, Matthew; Wander, Seth; Bachelot, Thomas; Batist, Gerald; Cortes, Javier; Cristofanilli, Massimo; Curigliano, Giuseppe; de Nonneville, Alexandre; Yam, Einav Nili-Gal; Jhaveri, Komal; Ma, Cynthia; Parsons, Heather; Rugo, Hope; Sammons, Sarah; Stover, Daniel; Twelves, Chris; Bardia, Aditya; Plourde, Paul V.; Portman, David J.; Damodaran, Senthil
err分享
err收藏
ASTEFANIA: a Phase III study of ado- trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy
err2024-05-02
err0
PREAI
errSchmid, Peter; Bachelot, Thomas; Bianchini, Giampaolo; Harbeck, Nadia; Loi, Sherene; Park, Yeon; Prat, Aleix; Gilham, Leslie; Boulet, Thomas; Gochitashvili, Nino; Monturus, Estefania; Lambertini, Chiara; Nyawira, Beatrice; Knott, Adam; Hurvitz, Sara
err分享
err收藏
Prognostic value of EndoPredict test in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
err2024-05-01
err0
errOAAI
errPenault-Llorca, F.; Dalenc, F.; Chabaud, S.; Cottu, P.; Allouache, D.; Cameron, D.; Grenier, J.; Bouvet, L. Venat; Jegannathen, A.; Campone, M.; Debled, M.; Hardy-Bessard, A. -C.; Giacchetti, S.; Barthelemy, P.; Kaluzinski, L.; Mailliez, A.; Mouret-Reynier, M. -A.; Legouffe, E.; Cayre, A.; Martinez, M.; Delbaldo, C.; Mollon-Grange, D.; Macaskill, E. J.; Sephton, M.; Stefani, L.; Belgadi, B.; Winter, M.; Orfeuvre, H.; Lacroix-Triki, M.; Bonnefoi, H.; Bliss, J.; Canon, J. -l.; Lemonnier, J.; Andre, F.; Bachelot, T.
err分享
err收藏